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OBJECTIVES These studies were conducted to evaluate the feasibility of percutaneous left atrial appendage
(LAA) occlusion using the PLAATO system (ev3 Inc., Plymouth, Minnesota).
BACKGROUND Patients with atrial fibrillation (AF) have a five-fold increased risk for stroke. Other studies
have shown that more than 90% of atrial thrombi in patients with non-rheumatic AF
originate in the LAA. Transvenous closure of the LAA is a new approach in preventing
embolism in these patients.
METHODS Within two prospective, multi-center trials, LAA occlusion was attempted in 111
patients (age 71  9 years). All patients had a contraindication for anticoagulation
therapy and at least one additional risk factor for stroke. The primary end point was
incidence of major adverse events (MAEs), a composite of stroke, cardiac or neurological
death, myocardial infarction, and requirement for procedure-related cardiovascular
surgery within the first month.
RESULTS Implantation was successful in 108 of 111 patients (97.3%, 95% confidence interval [CI]
92.3% to 99.4%) who underwent 113 procedures. One patient (0.9%, 95% CI 0.02% to 4.9%)
experienced two MAEs within the first 30 days: need for cardiovascular surgery and
in-hospital neurological death. Three other patients underwent in-hospital pericardiocentesis
due to a hemopericardium. Average follow-up was 9.8 months. Two patients experienced
stroke. No migration or mobile thrombus was noted on transesophageal echocardiogram at
one and six months after device implantation.
CONCLUSIONS Closing the LAA using the PLAATO system is feasible and can be performed at acceptable
risk. It may become an alternative in patients with AF and a contraindication for lifelong
anticoagulation treatment. (J Am Coll Cardiol 2005;46:9–14) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.042College of Cardiology Foundation
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Atrial fibrillation (AF) is responsible for more than 15% of all
trokes (1–3). Besides irregular heart rate and possible lowered
ndurance, AF leads to insufficient contraction of the left
trium. Stagnation of blood flow within the left atrium leads to
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‡Lancaster General Hospital, Lancaster, Pennsylvania; §§Columbia University, aypercoagulability and thus to an increased risk for thrombus
ormation (4). Several surgical, echocardiographic, and autopsy
tudies have shown that more than 90% of all thrombi in
atients with non-rheumatic AF forming in the left atrium
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The PLAATO System Trial July 5, 2005:9–14riginate in the left atrial appendage (LAA) (5–7). Therefore,
ccluding the LAA would seem to be a logical approach to
reventing thrombus formation and subsequent cardioembolic
vents in these patients.
A new device has been designed and developed that al-
ows percutaneous LAA transcatheter occlusion (PLAATO
ystem, ev3 Inc., Plymouth, Minnesota) via a trans-septal
pproach. It has been shown to be safe and effective in
ccluding the LAA in animal experiments (8).
Two concurrent feasibility studies were conducted, one in
urope and the other in North America. The purpose of
hese studies was to evaluate the feasibility, safety, and
erformance of the PLAATO system for LAA occlusion in
atients with non-rheumatic AF who were at high risk for
schemic stroke and not candidates for long-term anticoag-
lation with warfarin.
A small subset of this patient population has been pre-
iously reported (9,10).
ETHODS
tudy design. These were prospective, non-randomized,
ulti-center studies. Enrollment started in August 2001
nd finished in November 2003.
The primary study end point was the occurrence of major
dverse events (MAEs) within one month of the index
rocedure; MAEs were defined as new major or minor
troke, cardiac or neurological death, myocardial infarction,
r requirement for cardiovascular surgery related to the
LAATO procedure.
The secondary end points were to assess the ability of the
LAATO system to occlude the LAA and avoid MAEs
uring the initial hospitalization as well as MAEs and
ormation of mobile left atrial thrombus within six months
f the procedure.
There also were two device performance end points,
ncluding: 1) implantation success, defined as successful
elivery and deployment of the PLAATO implant into the
AA and the absence of MAEs within one month of the
ndex procedure; and 2) treatment success, defined as
uccessful delivery and deployment of the PLAATO im-
lant into the LAA and LAA occlusion, as visualized by the
nvestigator with angiography, immediately after placement
f the implant.
Serious adverse events (SAEs) were defined as any events
Abbreviations and Acronyms
AF  atrial fibrillation
CI  confidence interval
LAA  left atrial appendage
LVEF  left ventricular ejection fraction
MAE  major adverse event
SAE  serious adverse event
TEE  transesophageal echocardiogram
TIA  transient ischemic attackhat were fatal or life threatening, resulted in persistent orignificant disability, required surgical intervention or inten-
ive care unit treatment to prevent permanent impairment
r damage, or resulted in re-admission or prolongation of
ospitalization.
atients. The LAA occlusion was attempted in 111 pa-
ients with non-rheumatic AF of at least three months’
uration.
None of them were candidates for anticoagulation ther-
py, defined as having a contraindication to warfarin on the
asis of the warfarin product label.
To be eligible, the patients were required to have a history
f transient ischemic attack (TIA) or stroke or at least one
in Europe) or two (in North America) of the following risk
actors that put them at high risk for thromboembolic
vents: presence of congestive heart failure or a left ventric-
lar ejection fraction (LVEF) 40%; a history of systolic
ypertension 160 mm Hg; diabetes; age 65 years;
istory of myocardial infarction or known coronary stenosis
50%; and moderate or dense spontaneous echocardio-
raphic contrast or blood flow velocity 20 cm/s within the
AA.
Key criteria for exclusion were thrombus formation in the
eft atrium or LAA as well as complex aortic plaque, mitral
r aortic stenosis or regurgitation, left atrial diameter 6.5
m, acute myocardial infarction or unstable angina, and
ecent stroke (2 months) as well as symptomatic carotid
isease. Patient characteristics at baseline are summarized in
ables 1 and 2.
evice and implantation technique. The PLAATO de-
ice consists of a self-expanding nitinol cage (range of
iameter 15 to 32 mm) covered with expanded polytetra-
uoroethylene in order to close off blood flow into the
emaining part of the LAA. Three rows of anchors along
he struts help stabilize the occluder in the appendage.
All patients received aspirin (300 to 325 mg) twice a day
nd clopidogrel (75 mg) twice a day 48 h before the
rocedure as well as antibiotic therapy 1 h before the
ntervention. After venous and trans-septal puncture, the
evice was delivered under transesophageal echocardiogram
TEE) and fluoroscopic guidance through a specially de-
igned 12-F trans-septal sheath into the LAA. Heparin was
able 1. Patient Characteristics at Baseline
Patients (n  111)
ean age (yrs) 71
Standard deviation 9
Minimum 42
Maximum 90
ale 66 (59%)
uration of atrial fibrillation
1 yr 21 (19%)
1–3 yrs 34 (31%)
3 yrs 56 (50%)
ean left atrial appendage orifice diameter (mm) 22
Standard deviation 4
Minimum 11
Maximum 30
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July 5, 2005:9–14 The PLAATO System Trialdministered in order to keep the activated clotting time
bove 250 s. The initial device chosen was 20% to 50%
arger than the ostium of the LAA measured by angiogra-
hy and TEE. Both distal (through a special lumen in the
evice) and proximal (through the distal sheath in the left
trium) dye injections as well as TEE imaging assessed the
dequacy of occlusion of the LAA. If an inadequate seal or
ub-optimal position of the device was identified, the device
as collapsed and re-positioned or exchanged for a device of
ifferent size while trans-septal access was maintained.
The degree of sealing after device release was assessed by
roximal dye flow and subdivided into four categories:
ell-defined flow of dye completely filling the appendage
grade 1, “severe leak”); filling two-thirds (grade 2, “mod-
rate leak”); filling one-third (grade 3, “mild leak”); and
arely detectable or no detectable blush of dye flowing into
he appendage (grade 4, “trace leak” to “absent leak”). The
AA occlusion was defined as a leak of grade 3 or 4. The
resent study was the first to use the aforementioned
ngiographic grading to evaluate LAA occlusion. Addition-
lly, transesophageal Doppler color flow was assessed and
raded on a five-point scale: multiple jets of free flow (grade
, “severe leak”); 3 mm diameter jet (grade 2, “moderate
eak”); 1 to 3 mm diameter jet (grade 3, “mild leak”); 1
m diameter jet (grade 4, “trace leak”); no jet (grade 5,
absent leak”). Successful LAA occlusion was defined as a
rade of 3 or higher.
ollow-up. After LAA closure, patients were placed on
able 2. Pre-Procedural Stroke Risk Factors
Patients (n  111)
aseline clinical risk factors
Age 65 yrs 93 (84%)
Age 75 yrs 39 (35%)
Congestive heart failure or LVEF 40% 43 (39%)
Hypertension 80 (72%)
Diabetes mellitus 29 (26%)
Prior stroke or TIA 42 (38%)
Coronary artery disease 45 (41%)
High-risk TEE* 52 (47%)
atients’ CHADS2 score†
0 2 (2%)
1 27 (24%)
2 33 (30%)
3 23 (21%)
4 18 (16%)
5 7 (6%)
6 1 (1%)
verage CHADS2 score 2.5
Standard deviation 1.3
Defined as moderate or dense spontaneous echo contrast or blood flow velocity 20
m/s within the left atrial appendage. †The CHADS2 index calculates the individual
troke risk by assigning one point each for the presence of congestive heart failure,
ypertension, age 75 years, and diabetes, and two points for history of stroke or
ransient ischemic attack. Thus, CHADS2 is an acronym for risk factors and their
coring. The stroke rate per 100 patient-years under aspirin therapy rises with
ncreasing score: 0.8 with 0 points, 2.2 with 1 point, 4.5 with 2 points, 8.6 with 3
oints, 10.9 with 4 points, 12.3 with 5 points, and 13.7 with 6 points (23).
LVEF  left ventricular ejection fraction; TEE  transesophageal echocardio-
ram; TIA  transient ischemic attack.spirin (300 to 325 mg/day) indefinitely. In North America, tlopidogrel (75 mg/day) was prescribed for four to six weeks
s well as sub-acute endocarditis prophylaxis for the follow-
ng six months because of a possible increased risk for
nfective endocarditis (11). In the European protocol, clo-
idogrel and prophylactic antibiotic therapy were left to the
nvestigators’ discretion. Patients were followed with chest
-ray, transthoracic echocardiography, and clinical exami-
ations after procedure, at 1 week (in Europe), 1 month, 3
onths (in North America), 6 months, and 12 months.
In Europe, a TEE was obtained in all patients at one
onth. The first 20 patients enrolled in North America
eceived a TEE after one month and after six months as
ell. Transesophageal echocardiogram also was performed
t other times at the discretion of the investigator, if
linically indicated. All echocardiograms were evaluated by
core-laboratory.
tatistical analysis. Analyses were conducted on an intent-
o-treat basis. Continuous variables are summarized by
ean, standard deviation, and minimum and maximum
alues. Estimates for frequency of occurrence of events are
xpressed as percentages or rates with 95% confidence
ntervals (CIs).
thics. Subjects’ written informed consent was obtained,
nd the procedures were performed in accordance with the
thical standards of the responsible committee and with the
elsinki Declaration of 1975, revised in 1983.
ESULTS
ercutaneous LAA occlusion was successful in 108 of 111
atients (97.3%, 95% CI 92.3% to 99.4%). Three patients
id not receive a PLAATO device because of the presence
f a left atrial thrombus at the time of procedure (n  1),
ecause of vessel perforation of the right femoral artery
uring the attempt to access the right femoral vein (n  1),
nd because of a cardiac tamponade after trans-septal
uncture (n  1). The last-mentioned patient underwent
ericardiocentesis, median sternotomy, and ligation of the
AA 4 h after the index procedure. During hospitalization
he patient developed right leg deep vein thrombosis and
ied at 27 days after the procedure owing to probable
erebral hemorrhage after anticoagulation had been instituted.
The average LAA orifice diameter was 22  4 mm, and
he median implant size was 29 mm. Two patients received
n 18-mm device; 1 received a 20-mm; 7 received a 23-mm;
5 received a 26-mm; 33 received a 29-mm; and 50 received
32-mm occluder.
Fifty-five procedures (48.7%) were performed with local
nesthesia, and 58 (51.3%) were performed under general
nesthesia. The average procedure time was 68  28 min.
he average fluoroscopy time was 18  9 min.
Of the 108 patients in which device implantation was
uccessful, 100 (92.6%) received aspirin and 82 (75.9%)
eceived clopidogrel after the procedure.
uration of follow-up. All of the 108 patients completedheir one-month follow-up; 97 (89.8%), their six-month
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The PLAATO System Trial July 5, 2005:9–14ollow-up; and 74 (68.5%), their one-year visit. One patient
as lost to follow-up. The average follow-up was 9.8
onths, a total of 90.7 documented implant years.
rimary study end points. Of the 111 enrolled patients, 1
atient (0.9%, 95% CI 0.02% to 4.9%) experienced two
AEs within the first 30 days after procedure: need for
mergent cardiovascular surgery owing to cardiac tampon-
de, and neurological death in-hospital as previously
escribed.
econdary study end points. By six months after the
rocedure, the rate of patients that experienced no MAEs
nd/or mobile left atrial thrombus was 97.9% (95% CI
2.2% to 99.8%) on the basis of 95 of 97 patients with
ix-month follow-up. Two patients did not meet this end
oint: again, the aforementioned patient with two MAEs
uring the index hospitalization, and one patient who
xperienced an ischemic stroke 173 days after procedure.
evice performance end points. Implantation and treat-
ent success were achieved in 108 of 113 procedures (95.6%,
5% CI 90.0% to 98.6%) performed in 111 patients (97.3%,
5% CI 92.3% to 99.4%). Complete recapture and retrieval
as successful whenever necessary. Of the 108 implanted
evices, 94 (87.0%) showed “trace leak” to “absent leak” after
AA occlusion; 14 patients (13.0%) showed “mild leak.”
chocardiographic results. Immediately after the proce-
ure, 86 of 88 patients (97.7%, 95% CI 92.0% to 99.7%)
ith assessable TEE showed successful occlusion of their
ppendage. At one month, 60 of 60 patients (100%) met
his criterion (grade 3: 8 patients [13.3%]; grade 4: 31
atients [51.7%]; grade 5: 21 patients [35.0%]). At six
onths, 49 of 50 patients (98.0%, 95% CI 89.4% to 100%)
howed successful LAA occlusion (grade 2: 1 patient
2.0%]; grade 3: 5 patients [10.0%]; grade 4: 27 patients
54.0%]; grade 5: 17 patients [34.0%]). In one patient, TEE
evealed a laminar layer along the superior edge of the
ccluder at the six-month follow-up. With continuing
dministration of aspirin and clopidogrel this laminar
rowth resolved over the following six months, showing no
emaining material in the 12-month TEE. Echocardio-
raphic examinations showed no mobile thrombus and no
isruption of mitral valve function or pulmonary vein inflow
able 3. Left Atrial Appendage Occlusion Verified by
ransesophageal Doppler Color Flow and Angiography
Transesophageal
Doppler Color
Flow
Angiography
Severe
Leak
Moderate
Leak
Mild
Leak
Trace to
Absent Leak
evere leak — — — —
oderate leak — — — 2 pts
ild leak — — 5 pts 15 pts
race to absent leak — — 8 pts 58 pts
ransesophageal echocardiographic images were available from 88 patients after
rocedure. These two methods showed concurrence in 63 of 88 patients (71.6%) (5
atients  58 patients). Two patients had a “Moderate Leak” (grade 2) in
ransesophageal Doppler color flow, whereas the angiography showed “Trace Leak” to
Absent Leak” (grade 4).
pts  patients; other abbreviations as in Table 2.n any patient. The echocardiographic results matched the Mutcome of chest X-ray in excluding device migration or
islodgement from the LAA. The concurrence of trans-
sophageal Doppler color flow and angiography regarding
valuation of LAA occlusion is presented in Table 3.
dverse events. There were seven MAEs in five patients
Table 4). A total of nine procedure-related SAEs occurred
n seven patients. None of the SAEs were adjudicated to be
evice-related. Procedure-related SAEs included pleural
ffusion (n  1) and dyspnea requiring reintubation (n  1)
n one patient, pericardial effusion in two patients (n  2),
nd cardiac tamponade in two patients (n  2). In three of
hem, pericardiocentesis was performed. One patient also
eveloped a left-sided hemothorax (n  1) that was noted
n the first day after the procedure and was treated by
horacocentesis. One patient experienced right leg deep vein
hrombosis (n  1), and another patient developed brachial
lexus palsy (n  1).
ncidence of stroke and TIA. Of the 111 enrolled pa-
ients, 2 (1.8%, 95% CI 0.2% to 6.4%) experienced a stroke
73 and 215 days after the implant procedure. In both
atients, TEE performed at the one- and six-month
ollow-up showed the device in stable position with no
hrombogenic layer on the device surface. Doppler color
ow at six months showed “trace leak” and “absent leak” in
hese two patients. Three TIAs occurred in two patients.
he observed annual stroke rate was 2.2% (two events
uring 90.7 documented implant years).
eaths. There were six deaths in 111 patients (5.4%).
one were adjudicated as device- or procedure-related. The
auses of death included cardiac or neurological death (n 
), secondary complications after gastrointestinal bleeding
n  1), and an incarcerated hernia (n  1).
ISCUSSION
trial fibrillation, whether intermittent or sustained, in-
reases the risk for cardioembolic events leading to an
verall annual stroke rate of 4.5%/year (12–14). Anticoag-
lation is highly effective in preventing embolic events in
hese patients. With a risk reduction of almost 70%, it is
uperior to aspirin and aspirin plus low-intensity, fixed-dose
arfarin treatment (13,15,16). Moreover, the use of warfa-
in has a narrow therapeutic range. Restrictions in everyday
ife, pharmacological interactions, and the potential risk of
ajor hemorrhage limit this method of treatment (15,17).
hese concerns lead to an extensive anticoagulation under-
able 4. Occurrence of MAEs During 90.7 Documented
mplant Years
MAE Patients (n  111)
ajor or minor stroke 2
yocardial infarction 0
equirement for cardiovascular surgery related to
PLAATO procedure
1
ardiac or neurological death 4
ny MAE 7 (in 5 patients)AE  major adverse event.
u
b
m
f
r
k
fl
q
t
r
r
a
s
e
w
t
o
a
fi
t
t
y
r
m
A
t
p
L
a
m
f
s
o
t
c
s
f
a
t
O
f
d
(
p
a
T
C
s
p
S
a
s
i
m
s
i
p
p
F
a
C
p
s
i
o
s
a
m
w
t
c
A
T
B
F
a
R
d
F
R
13JACC Vol. 46, No. 1, 2005 Ostermayer et al.
July 5, 2005:9–14 The PLAATO System Trialse in general clinical practice (18,19). Furthermore, the
enefit of anticoagulation as compared with aspirin treat-
ent is more substantial in patients who are at higher risk
or stroke (15,16). Yet these patients are more likely to have
elative or absolute contraindications to warfarin treatment.
Percutaneous LAA occlusion is an improved method of a
nown approach (7,20,21), excluding the LAA from blood
ow and thus preventing thrombus formation and subse-
uent thromboembolic complications. The advantages of
his technique include a less invasive procedure, a faster
ecovery as compared with surgical ligation, and the reduced
isk of potential bleeding owing to the absence of long-term
nticoagulation therapy.
In our cohort of 111 patients, device implantation was
uccessful in all but 3 patients. Five patients (4.5%) experi-
nced pericardial effusions or hemopericardia that were
ithout sequelae in four patients. In two of the four patients
hat required pericardiocentesis, however, this incidence
ccurred due to catheter manipulation during the attempt to
ccess the LAA after trans-septal puncture. They were the
rst treated patients at a new site. It can be assumed that
his number will decrease with increased experience with
his new technique.
Five patients experienced MAEs during follow-up (5.5%/
ear). In the Second Copenhagen Atrial Fibrillation, Aspi-
in and Anticoagulation Study (22), the risk of stroke,
yocardial infarction, and vascular death in patients with
F receiving only aspirin therapy was 4.7%/year (intention-
o-treat analysis).
Although the intention of closing the LAA is stroke
revention, the primary aim of this study was to show that
AA occlusion using the new PLAATO device is feasible
nd can be performed at acceptable risk. In order to make a
ore definitive statement on reduction of stroke, longer
ollow-up is needed. As of December 2003, the annual
troke rate of the 108 patients that underwent successful
cclusion of their LAA was 2.2%. The cause of stroke in
hese patients remained uncertain. Transesophageal echo-
ardiogram performed shortly before and after these events
howed sufficient occlusion of the LAA with no thrombus
ormation on the device surface. This would seem to suggest
non-cardioembolic origin and, more importantly, shows
hat LAA occlusion cannot protect from all ischemic events.
n the basis of the patients’ CHADS2 score (an acronym
or congestive heart failure, hypertension, age 75 years,
iabetes mellitus, and stroke or transient ischemic attack)
2.5 points) (23), the estimated annual stroke rate for this
atient population was 6.3%, assuming they were taking
spirin; this means the relative stroke reduction was 65%.
he expected stroke rate may be even higher, since the
HADS2 index does not take echocardiographic results
uch as dense spontaneous echo contrast, a powerful stroke
redictor (24), into its calculation.
tudy limitations. This was a non-randomized study with
relatively selected patient population. Calculating theirtroke risk by using the CHADS2 score may only give andea of what the expected risk for stroke in these patients
ay be. Furthermore, the follow-up period of the present
tudy was limited to a maximum of 17 months after device
mplantation. Further studies are necessary to evaluate the
erformance of the PLAATO device regarding stroke
revention and the long-term tolerance of the device.
urther limitations include the limited numbers of assess-
ble TEEs during follow-up.
onclusions. The results of the present study show that
ercutaneous LAA occlusion using the new PLAATO
ystem can be performed at acceptable risk. Because it is less
nvasive, this technique is more practical for a large number
f patients compared with surgical closure. Longer-term
tudies are needed to confirm long-term safety of the device
nd a reduction in thromboembolic events. This technique
ay become an alternative therapeutic strategy for patients
ith AF who are at increased risk for ischemic stroke and,
herefore, should receive anticoagulation therapy, but have a
ontraindication for long-term warfarin treatment.
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